Lipoprotein(a) level and apolipoprotein(a) phenotype as predictors of long-term cardiovascular outcomes after coronary artery bypass grafting

This publication has 29 references indexed in Scilit:

• Effects of Aggressive Statin Therapy on Patients With Coronary Saphenous Vein Bypass Grafts: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials
  Clinical Therapeutics, 2013
• Lipoprotein(a) as a cardiovascular risk factor: current status
  European Heart Journal, 2010
• Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy
  Journal of Lipid Research, 2010
• Apolipoprotein(a) Isoforms and the Risk of Vascular Disease
  JACC, 2010
• Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
  JAMA, 2009
• Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions
  Clinical Chemistry, 2003
• Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery
  The Journal of Thoracic and Cardiovascular Surgery, 2003
• Influence of serum lipoprotein(a) and homocyst(e)ine levels on graft patency after coronary artery bypass grafting
  The American Journal of Cardiology, 1994
• cDNA sequence of human apolipoprotein(a) is homologous to plasminogen
  Nature, 1987
• The Relation of Risk Factors to the Development of Atherosclerosis in Saphenous-Vein Bypass Grafts and the Progression of Disease in the Native Circulation
  New England Journal of Medicine, 1984